

Comparison of Generic Methods for the Quantification of Pembrolizumab Using Gyrolab™ and LC-MS/MS

Robert Stewart

YSS Conference 25th September 2020

25th September 2020

Copyright © 2020 Covance. All Rights Reserved.




COVANCE

Project Aims


- 1** Investigate generic PK methods for quantification of mAbs in preclinical species
- 2** Use Pembrolizumab to compare generic LBA on Gyrolab™ with signature peptide quantification by LC-MS
- 3** Quantify the impact of Anti-Drug Antibodies on Gyrolab™ and LC-MS

Pembrolizumab – Mode of Operation

- ▶ Humanized IgG4 monoclonal antibody
- ▶ Targets programmed cell death receptor (PD-1)
 - Binding to PD-1 on T cells to prevent binding to PDL-1 on tumor cell triggering programmed cell death
 - Therefore re-establishing T cell mediated anti-tumor response
- ▶ We want to prepare for next wave of combination pharmaceuticals used in conjunction with this therapy



Inhibition of T cell mediated anti-tumour response



Restoration of T cell mediated anti-tumour response

Generic LC-MS Method Based on Literature Method




© AB Sciex Pte. Ltd. – used with permission

Method: LC-MS/MS

- ▶ Tryptic digestion and SPE, followed by LC with MS detection, SILu™ Mab K1 as internal standard (stable label)
- ▶ Calibration standards (Cals) and quality controls (QCs) prepared in nonhuman primate (NHP) serum
- ▶ C18 column coupled with AB Sciex 6500+
- ▶ 15 µL sample volume to accommodate micro sampling


Method Development

1. Digestion and MS optimization of Pembrolizumab
2. Accuracy and precision
3. Immunogenicity interference test



LC-MS/MS: Infusion of Pembrolizumab

Peptide Name	Sequence	IgG Subclass
Peptide 1	VVSVLTVLHQDWL NGK	IgG1, IgG4, IgG3
Peptide 2	GFYPSDIAVEWES NGQPENNYK	IgG1, IgG4
Peptide 3	DSTYSLSSTLTLSK	All
Peptide 4	VDNALQSGNSQE SVTEQDSK	All



LC-MS/MS: Accuracy and Precision (A&P) Run

What was done?

- ▶ Analysed 1 A&P Run 500 ng/mL to 500,000 ng/mL analysed in singlicate
- ▶ Six QC levels, each with 6 replicates: LLOQ – 500 ng/mL and ULOQ – 400 µg/mL

Replicate	Intra-Assay Precision and Accuracy of Quality Control Sample Data									
	LLOQ QC		LQC		LMQC		MQC		HQC	
	500 ng/mL		2000 ng/mL		20,000 ng/mL		200,000 ng/mL		400000 ng/mL	
	Concentration (ng/mL)	%Bias	Concentration (ng/mL)	%Bias	Concentration (ng/mL)	%Bias	Concentration (ng/mL)	%Bias	Concentration (ng/mL)	%Bias
1	545	9.0	1590	-20.5	17600	-12.0	185000	-7.5	344000	-14.0
2	515	3.0	1750	-12.5	19400	-3.0	-	-	361000	-9.8
3	488	-2.4	2030	1.5	19200	-4.0	185000	-7.5	373000	-6.8
4	508	1.6	1690	-15.5	19800	-1.0	189000	-5.5	368000	-8.0
5	511	2.2	2050	2.5	20100	0.5	199000	-0.5	422000	5.5
6	613	22.6	2180	9.0	22300	11.5	220000	10.0	427000	6.8
Precision (%)		8.4		12.6		7.8		7.6		8.9
Bias (%)		6.0		-6.0		-1.5		-2.0		-4.3

Generic Gyrolab™ method using commercial kit by Gyros™



© Gyros – Picture used with permission


COVANCE

Method: Gyrolab™

- ▶ Used the Gyrolab™ generic PK kit
- ▶ Cals and QCs prepared in nonhuman primate (NHP) serum
- ▶ 10 µL sample volume used

Method Development

1. Reagent and assay range test
2. Accuracy and precision
3. Immunogenicity interference test



© Gyros – Picture used with permission

Gyrolab™: Accuracy and Precision (A&P) Run

What was done?

- ▶ Analysed 3 A&P Runs 20 ng/mL to 15,000 ng/mL analysed in singlicate
- ▶ 6 QC levels, with 6 replicates each: LLOQ QC (20 ng/mL)

Inter-Assay Precision and Accuracy of Quality Control Sample Data

	LLOQ 20 ng/mL	LQC 60 ng/mL	LMQC 660 ng/mL	MQC 7500 ng/mL	HQC 10000 ng/mL	ULOQ 15,000 ng/mL
Mean (ng/mL)	24.51	58.41	757.64	7845.90	14727.49	14962.97
Precision (%)	17.57	18.74	9.32	14.04	24.24	20.00
Bias (%)	22.53	-2.65	14.79	4.61	5.10	-0.24

How Do Anti-Drug Antibodies Affect the Bioanalysis?

Immunogenicity Interference Test

Influence of anti-pembrolizumab antibodies on assay performance

Adding three different concentrations LQC & HQC samples

- ▶ Gyrolab™: ADA = big effect
- ▶ LC-MS = no interference

	Gyrolab		LC-MS/MS	
QC level (ng/mL)	LQC (450 ng/mL)	HQC (8,000 ng/mL)	LQC (2,000 ng/mL)	HQC (40,000 ng/mL)
pAb concentration (ng/mL)	%Bias			
0	12.5	3.0	-6.0	-4.3
FDA REQUIRED SENSITIVITY 100	-13.0	-14.9	16.9	1.6
1,000	-54.3	11.1	13.7	-3.4
10,000	-98.1	-27.8	-17.1	-1.6

Summary of Methods

Parameter	LC-MS/MS	Gyrolab™
Assay Sensitivity (ng/mL)	500	20
Assay Range (ng/mL)	500 – 500,000 (1000 fold)	20 – 15,000 (750 fold)
Accuracy and Precision	% CV < 13 % Bias < 6	% CV < 25 % Bias < 25
Sample Volume (µL)	15	10
Assay Time (h)	7.5	1.5
Influence of ADA	Low/None	High
Application	Toxicokinetics	Pharmacokinetics

Any Questions?

Project completed by Rebecca Taylor – University of Leeds
Biopharmaceutical masters

Thanks to the following for their contributions to the project –
Rebecca Taylor – University of Leeds Biopharmaceutical masters

- Barry Hawthorne
- Gregory Bogle
- Emma Tipping
- Sam Willcox
- Sarah Malpas
- Johannes Stanta



Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries.

COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.

www.covance.com